Kamiya H, Arai S, Kawai K, Ihara T, Sakurai M, Shimizu S, Kodama K, Iwasa T, Inoue M, Kojima M
Jpn J Antibiot. 1987 Apr;40(4):867-82.
Cefuzoname (CZON) was administered to 50 pediatric patients with infections, and the efficacy was investigated in 49 patients. The efficacy rate was 83.7% and the drug was evaluated to be highly effective for diseases in the pediatric field. The activity of CZON was especially good against Staphylococcus aureus, and the efficacy rate for 13 clinical isolates was 69.2%, which was comparable to that of cefotiam or cefazolin. CZON appeared to be useable alone in Gram-positive infections. It might be very powerful in the control of infections in secondary immunodeficiency.
对50例感染性儿科患者使用头孢唑南（CZON），并对49例患者的疗效进行了研究。有效率为83.7%，该药物在儿科领域疾病方面被评估为高效。头孢唑南对金黄色葡萄球菌的活性尤其良好，对13株临床分离株的有效率为69.2%，与头孢替安或头孢唑林相当。头孢唑南似乎可单独用于革兰氏阳性菌感染。它在控制继发性免疫缺陷中的感染方面可能非常有效。
